Insider Selling: Heron Therapeutics Inc (NASDAQ:HRTX) VP Sells 24,000 Shares of Stock

Share on StockTwits

Heron Therapeutics Inc (NASDAQ:HRTX) VP Kimberly Manhard sold 24,000 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $26.00, for a total transaction of $624,000.00. Following the sale, the vice president now owns 24,000 shares of the company’s stock, valued at $624,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

HRTX stock traded up $0.44 during trading on Tuesday, reaching $26.61. The company had a trading volume of 751,488 shares, compared to its average volume of 987,484. Heron Therapeutics Inc has a 52 week low of $15.68 and a 52 week high of $29.49. The company has a market cap of $2.40 billion, a P/E ratio of -10.91 and a beta of 1.53. The business has a 50 day moving average of $21.55 and a 200 day moving average of $19.04. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.76 and a quick ratio of 3.51.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.15. The business had revenue of $42.62 million for the quarter, compared to analysts’ expectations of $34.02 million. Heron Therapeutics had a negative return on equity of 60.76% and a negative net margin of 140.55%. The business’s revenue was up 115.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.49) EPS. Research analysts expect that Heron Therapeutics Inc will post -2.44 earnings per share for the current year.

Several large investors have recently made changes to their positions in the company. Meadow Creek Investment Management LLC purchased a new position in shares of Heron Therapeutics in the 2nd quarter valued at approximately $27,000. Quantum Capital Management bought a new position in shares of Heron Therapeutics in the 3rd quarter worth about $53,000. US Bancorp DE increased its stake in shares of Heron Therapeutics by 75.6% in the 2nd quarter. US Bancorp DE now owns 4,108 shares of the biotechnology company’s stock worth $76,000 after acquiring an additional 1,769 shares in the last quarter. Tower Research Capital LLC TRC bought a new position in shares of Heron Therapeutics in the 3rd quarter worth about $100,000. Finally, Tiverton Asset Management LLC purchased a new position in Heron Therapeutics during the 2nd quarter valued at about $101,000.

Several equities research analysts have weighed in on HRTX shares. Stifel Nicolaus reiterated a “buy” rating and issued a $38.00 price objective on shares of Heron Therapeutics in a report on Monday, August 5th. Zacks Investment Research raised Heron Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Friday, November 15th. Svb Leerink reissued an “outperform” rating on shares of Heron Therapeutics in a research note on Tuesday, November 12th. Cowen restated a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a report on Tuesday, October 1st. Finally, JMP Securities dropped their price target on Heron Therapeutics from $38.00 to $32.00 and set a “market outperform” rating for the company in a research note on Thursday, October 3rd. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Heron Therapeutics presently has an average rating of “Buy” and an average target price of $46.13.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: Price to Earnings Ratio (PE)

Insider Buying and Selling by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.